Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Latvia Pharmaceuticals And Healthcare
Industry SWOT — 6
Latvia Political
SWOT — 7
Latvia Economic SWOT — 7
Latvia Business Environment SWOT — 8
Pharmaceutical
Business Environment Ratings — 9
Table: Regional Pharma
Business Environment Ratings — 9
Limits of Potential
Returns — 10
Risks to Realisation of
Returns — 10
Latvia – Market
Summary — 12
Regulatory Regime — 13
Regional Collaboration — 13
Corruption — 14
Intellectual Property
Developments — 14
Pricing Regime — 15
Reimbursement Regime — 16
Industry
Developments — 17
Epidemiology — 17
Healthcare Sector — 19
Healthcare
Provision — 19
Pharmaceutical
Industry — 20
Recent Pharmaceutical Company
Developments — 21
Pharmaceutical
Wholesale — 23
And Distribution — 23
Pharmaceutical Retail — 23
Table: Latvia Pharmacies And
Pharmacy Market Ratios, 2004-2009 — 25
Biotechnology — 25
Clinical
Trials — 25
Medical Devices — 26
Industry Forecast Scenario — 27
Overall Market
Forecast — 27
Table: Latvia - Drug Expenditure Indicators,
Historical Data And Forecasts, 2003-2013 — 28
Key Growth
Factors – Industry — 29
Table: Latvia – Health
Expenditure Indicators, Historical Data And Forecasts,
2003-2013 — 30
Key Growth Factors –
Macroeconomic — 31
Table: Latvia – Economic
Activity, 2006 – 2013 — 32
Prescription Market
Forecast — 33
Table: Latvia – Prescription Market
Indicators, Historical Data And Forecasts (LVLmn unless otherwise
stated) — 34
Patented Market
Forecast — 35
Table: Latvia – Patented Drug Market
Indicators, Historical Data And Forecasts, 2003-2013 — 35
Generics Market Forecast — 36
Table: Latvia –
Generics Market Indicators, Historical Data And Forecasts,
2003-2013 — 37
OTC Market
Forecast — 38
Table: Latvia – OTC Market Indicators,
Historical Data And Forecasts (LVLmn unless otherwise stated),
2003-2013 — 39
Export/Import
Forecasts — 40
Table: Latvia – Pharmaceutical Trade
Indicators, Historical Data And Forecasts, 2003-2013
(US$mn) — 41
Other Healthcare Data
Forecasts — 42
Table: Latvia – Other Healthcare
Indicators, Historical Data And Forecasts, 2003-2013 — 42
Key Risks To BMI’s Forecast Scenario — 43
Competitive Landscape — 44
Company
Monitor — 45
Multinational Company
Profiles — 45
Pfizer — 45
GlaxoSmithKline — 46
Sanofi-Aventis — 47
Novartis — 48
Merck & Co — 49
Indigenous Company
Profiles — 50
Grindeks (includes Tallinn Pharmaceutical
Plant) — 50
Olainfarm — 55
Country
Snapshot: Latvia Demographic Data — 57
Section 1:
Population — 57
Table: Demographic Indicators,
2005-2030 — 57
Table: Rural/Urban Breakdown,
2005-2030 — 58
Section 2: Education And
Healthcare — 58
Table: Education,
2002-2005 — 58
Table: Vital Statistics,
2005-2030 — 58
Section 3: Labour Market And Spending
Power — 59
Table: Employment Indicators,
2001-2006 — 59
Table: Consumer Expenditure, 2000-2012
(US$) — 60
Table: Average Annual Wages,
2000-2012 — 60
BMI Forecast
Modelling — 61
How We Generate Our Pharmaceutical Industry
Forecasts — 61
Pharmaceutical Business Environment Ratings
Methodology — 62
Ratings Overview — 62
Table: Pharmaceutical Business Environment Indicators — 63
Weighting — 64
Table: Weighting Of
Components — 64
Sources — 64
| 
View Cart
